| 07/01/22 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 06/01/22 | Notification about results of final buy-back of shares | AQ |
| 30/12/21 | Notification about final share buy-back | AQ |
| 28/12/21 | Correction: Regarding results of a share buy-back offer | AQ |
| 28/12/21 | On substantial participation (4) - specified | AQ |
| 1 day | -0.24% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 01/01/2026 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 01/01/2010 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 19/06/2021 | |
Janis Buks
CHM | Chairman | - | 01/09/2022 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.24% | -3.46% | - | - | 148M | |
| -0.23% | +0.82% | +7.01% | +82.47% | 45.63B | |
| +0.29% | -3.03% | +41.83% | +84.69% | 33.53B | |
| -0.67% | -0.57% | -9.63% | +38.25% | 11.81B | |
| -1.36% | +0.15% | +11.78% | +98.34% | 11.69B | |
| +3.11% | +0.78% | +36.70% | +129.46% | 9.12B | |
| -0.75% | -2.47% | +17.93% | +41.29% | 7.16B | |
| +2.37% | +0.76% | +45.05% | -15.33% | 6.49B | |
| -0.71% | -0.78% | +28.28% | +236.14% | 6.45B | |
| +0.51% | -3.04% | -43.06% | -3.48% | 5.16B | |
| Average | +0.23% | -0.07% | +15.10% | +76.87% | 15.23B | |
| Weighted average by Cap. | +0.08% | -0.30% | +17.97% | +80.90% |
Employees
2,191
Sector
Pharmaceuticals
